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Uncontrolled growth of malignant cells produces hypoxic regions in locally advanced tumors.
Recently we showed that tumor hypoxia-induced transcription of multiple genes involved in glycan
synthesis, leading to expression of useful glycolipid tumor markers, such as gangliosides having N-
glycolyl sialic acid. Our subsequent studies indicated that the ceramide portion of glycolipids, as
well as their glycan moiety, was also signiﬁcantly affected by hypoxia. Tumor hypoxia-induced
marked accumulation of sphinganine (dihydrosphingosine) long-chain base, and signiﬁcant reduc-
tion of unsaturated very long-chain fatty acids in the ceramide moiety. Mass-spectrometry, which
yields information on both glycan- and ceramide moieties, is expected to be clinically useful in
detecting such distinct molecular species of cancer-associated glycolipids having combined alter-
ation in both glycan- and ceramide moieties.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction one of the major mechanisms for induction of cancer-associatedCell-surface glycolipids are known to undergo drastic changes
upon malignant transformation [1,2]. Glycolipids appearing in can-
cer cells are shown to serve as good tumor markers, and applied
also as therapeutic targets of cancers [3,4]. The mechanisms under-
lying tumor-associated changes of glycolipids, however, are com-
plicated and remain elusive. Some changes occur at the relatively
early stages of carcinogenesis, while some other changes become
apparent only in the advanced stages along with progression of
cancers. In the stages of locally advanced cancers, uncontrolled
growth of tumor cells produces hypoxic areas in expanded cancer
cell nests. Tumor hypoxia affects various aspects of intracellular
metabolisms of cancer cells, and recently it was disclosed to bechemical Societies. Published by E
ramide monohexose; DHCer,
xose; DHSph, dihydrosphing-
/MS, high-performance liquid
mass spectrometry; HRE,
MALDI-MS, matrix-assisted
sialic acid; NeuGc, N-glycolyl
ngomyelin; VLCFA, very long-
olecular Pathology, Research
aku, Nagoya 464-8681, Japan.
i).glycans in glycolipids and glycoproteins. Here we introduce the no-
tion that tumor hypoxia affects not only the glycan moiety of gly-
colipids, but also their ceramide moiety.
2. Hypoxia and cancer-associated glycolipids
Recently we showed that tumor hypoxia leads to enhanced
expression of some cell-surface glycans, that had been well known
to be associated with cancers, such as sialyl Lewis X and sialyl Le-
wis A. This turned out to be due to induction of the transcription of
the genes involved in the synthesis of these glycans by hypoxia as
analyzed by DNA microarray [5]. Since then, it is becoming clearer
year after year that tumor hypoxia affects a wide variety of genes
involved in the expression of cell-surface glycoconjugates, and in-
duces profound changes in the expression of glycolipids and glyco-
proteins in cancers.
For instance, it has long been known that gangliosides carrying
N-glycolyl sialic acid increases in human cancers. Such ganglio-
sides are sometimes called Hanganatziu–Deicher antigens [6,7].
Recently we have shown that hypoxia-induced up-regulation of a
gene for the sialic acid transporter, Sialin, is closely related to the
enhanced expression of gangliosides carrying N-glycolyl sialic acid
(Fig. 1) [8]. Humans lack the gene for CMP-neuraminic acid
hydroxylase, the enzyme required to synthesize N-glycolyl sialic
acid (NeuGc), and most NeuGc in the human body is thought tolsevier B.V. All rights reserved.
Fig. 1. Hypoxia-induced expression of ganglioside GM2 having N-glycolyl sialic
acid. (Panel A) Flow-cytometric analysis of a clone of human cultured colon cancer
cells Caco-2M using monoclonal antibody speciﬁc to NeuGc-GM2 (MK2-34)
indicating prominent induction of the ganglioside by hypoxia. (Panel B) RT-PCR
analysis of transcriptional induction of the gene for a sialic acid transporter, Sialin,
by hypoxia in Caco-2M cells. (Panel C) Results of ﬂow-cytometric analysis of Caco-
2M cells indicating transfection of Sialin gene confers signiﬁcant NeuGc-GM2
expression. (Panel D) Immunohistochemical staining of NeuGc-GM2 in a colon
cancer tissue using speciﬁc monoclonal antibody, indicating the ganglioside serves
as a good marker for advanced stage cancer cells. Advanced cancer cells acquire
hypoxia-tolerance, and this accompanies sustained Sialin expression. (Upper panel)
Non-malignant colonic epithelial cells. (Lower panel) Cancer cell nests.
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[9,10]. Tumor hypoxia induces transcription of Sialin, and enhances
incorporation of exogenous sialic acid. This leads to enhanced
incorporation of NeuGc as well as N-acetyl sialic acid (NeuAc),
and results in signiﬁcant accumulation of unusual gangliosides car-
rying N-glycolyl sialic acid in cancers. Such gangliosides serve as
surrogate markers for the presence of cell masses suffering from
chronic hypoxia.
De novo synthesis of N-glycolyl sialic acid is based on oxida-
tive hydroxylation of N-acetyl sialic acid catalyzed by CMP-NeuAc
hydroxylase, a speciﬁc oxidase, expression of which is phyloge-
netically well controlled; it is present in mammals up to higher
apes, but absent in humans [11–13]. As the conversion of N-acet-
yl to N-glycolyl sialic acid is based on oxidative hydroxylation,
production of NeuGc through de novo synthesis may be sup-
pressed under hypoxic conditions in mammals up to higher apes.
In contrast, the expression of NeuGc rather increases under hyp-
oxic conditions in humans, where its level is determined by its
salvaging through the transporter Sialin, instead of de novo
synthesis.
Effects of hypoxia are not limited to changes in sialic acid
molecular species, but sometimes extend to the glycan backbone
of gangliosides. Marked induction of GD3 expression and moderate
induction of that of GM3 were observed in this cell line after hyp-
oxic culture (Fig. 2A). This was accompanied by a prominent induc-
tion of ST8Sia-I transcription (Fig. 2B). The ST3GalV gene shows a
delayed moderate induction, while genes for other glycosyltrans-
ferases show only minimal changes.
3. Ceramide composition and tumor hypoxia
During the course of study of tumor-associated gangliosides, we
have noticed that signiﬁcant changes occur at the ceramide moiety
as well as carbohydrate moiety of the gangliosides during hypoxia.
This was initially noticed from changes in the mobilities of gangli-
oside bands in TLC-immunostaining with speciﬁc anti-ganglioside
antibodies after hypoxic culture. Broadening of the main band and
appearance of additional slow-migrating band were frequently ob-
served, which implied altered ceramide composition in ganglio-
sides by hypoxia.
Analyses of sphingolipid molecular species by high-perfor-
mance liquid chromatography–electrospray ionization-tandem
mass spectrometry (HPLC–ESI-MS/MS) indicated a signiﬁcant
accumulation of dihydroceramide (DHCer) under hypoxia
(Fig. 3A). A similar accumulation of DHCer moiety was detected
also in the glycolipid and sphingomyelin (Sph) fraction (Fig. 3A).
This was accompanied with the decrease in ceramide moiety with
d18:1 long-chain base (LCB) (Fig. 3B). It is interesting to note that
the ratio of sphingosine/sphinganine is reportedly decreased in
certain tumors both in ceramide and Sph fractions in the literature
[14,15].
Another notable ﬁnding was a sharp decrease in the amount
of unsaturated very long-chain fatty acids (VLCFAs) in the cera-
mide moiety by hypoxia. C24:1 was the major unsaturated acyl
chain in the given cells, and its amount exhibited a marked de-
crease by hypoxia, and tended to recover after reoxygenation.
This was accompanied by an increase of saturated VLCFAs by hy-
poxia, which was most prominent with C22:0 species. Accord-
ingly, the ratio of unsaturated/saturated VLCFAs showed a
sharp reduction upon hypoxic culture, and tended to recover
after reoxygenation in all tested sphingolipid fractions (Fig. 3C),
reﬂecting impaired desaturase reaction for VLCFAs under hypoxic
condition.
Subsequent RT-PCR analysis (Fig. 3D) indicated a signiﬁcant
enhancement of transcription of fatty acid 2-hydroxylase (FA2H),
Fig. 2. Hypoxia-induced induction of ganglioside GD3. (Panel A) Flow-cytometric
analysis of a cultured human colon cancer cell line, LS174T, using monoclonal
antibodies speciﬁc to GD3 (GMR19) and GM3 (M2590). (Panel B) RT-PCR analysis of
transcriptional induction of genes involved in GD3 synthesis by hypoxia in LS174T
cells.
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Delta4-desaturase-1/2 (DES1/2) transcription. Lack of DES1 induc-
tion indicated that the impaired DHCer desaturation due to paucity
of oxygen is not going to be compensated by the induction of gene
transcription. The increase of DHCer species in sphingolipids by
hypoxia seems to simply reﬂect the uncompensated result of oxy-
gen deprivation. At this moment the relationship between changes
in LASS (CerS) and SPTLC (SPT) transcription and alteration of cera-
mide acyl chain composition is not clear. The increase in FA2Hmay
be related to the appearance of slow-migrating band in TLC-
immunostaining.
The FA2H and DES1/2 products require oxygen in their catalytic
action. It is highly conceivable that such enzymes requiring oxygen
would increase under hypoxic conditions to cope and compensate
for the paucity of oxygen. It, however, seems to apply to only a part
of such enzymes, in this case, FA2H, and does not apply to others
such as DES1/2. In the latter case, the deﬁciency of oxygen would
be straightforwardly reﬂected in changes in the ceramide compo-
sition of glycolipids.4. Pathophysiological signiﬁcance of hypoxia-induced
alteration of glycolipids
Cancer cells must cope with hypoxic environment to survive
and expand the size of tumors. Thomlinson–Gray’s equation on tis-
sue oxygen diffusion [16] indicates that cancer cells in an area
more than 75 lm distant from a blood vessel suffers from hypoxia,
where oxygen tension becomes less than 10 mmHg. The major
metabolic change in cancer cells induced by hypoxia is known to
be elevated anaerobic glycolysis, accompanied by increased pro-
duction of angiogenic factors. Enhanced expression of selectin li-
gand glycans such as sialyl Lewis A and sialyl Lewis X confers a
growth advantage to cancer cells under hypoxic environment, be-
cause they mediate adhesion of cancer cells to endothelial cells
expressing selectins. Induction of genes involved in sialyl Lewis A
and sialyl Lewis X by hypoxia is closely involved in tumor angio-
genesis [17] and hematogenous metastasis [18–20]. Hypoxia is
known to also induce sphingosine kinase-1, and enhances synthe-
sis of sphingosine-1-phosphate, which reportedly has a strong
angiogenic activity [21,22].
The advantage for cancer cells of enhanced sialic acid transport
through sialin is not clear at this moment. Cancer cells generally
have enhanced cell-surface sialylation, and have increased demand
for sialic acid donors for use in the synthesis of sialylated glycans.
Uptake and reuse of sialic acids through the transporter may econ-
omize on energy required for their de novo synthesis.
The accumulation of ceramide moieties having a d18:0 long-
chain base, and decrease in unsaturated N-acyl chains seems to re-
ﬂect a passive consequence of oxygen deprivation, rather than an
active accommodation of the cells to hypoxic environments. In
addition, the difference between cancers and normal cells is usu-
ally only quantitative, and not qualitative. Still it is noteworthy
that DHCer has been known to have much reduced activity in
inhibiting cell growth and inducing apoptosis [23]. This may confer
an additional growth advantage to cancer cells accumulating
DHCer.
Hypoxia-induced alteration in long-chain base and acyl chain
composition of ceramide moiety may also inﬂuence the physico-
chemical properties and affect microdomain formation and signal
transduction of cancer cells [24–28]. Accumulation of sphinganine
long-chain base and decrease in unsaturated very long-chain fatty
acids seem to favor more enhanced segregation of sphingolipid-en-
riched domains.5. Mechanisms for gene transcription induced by tumor
hypoxia
A transcription factor called hypoxia-inducible factor (HIF) ﬁg-
ures heavily in gene transcription induced by hypoxia. Although
several genes are known to be induced by hypoxia independent
of HIF, HIF is the major player in the gene transcription in hypoxia.
The a-subunit of HIF usually resides in cytoplasm, and is rapidly
ubiquitinated and degraded in proteasomes under normoxic condi-
tions. Ubiquitination stops under hypoxic conditions due to oxygen
sensing by proline hydroxylases and several other molecules, and
this leads to nuclear translocation of a-subunit, where it forms
an active heterodimer with the b-subunit present in the nucleus,
and induces transcription of genes having a hypoxia-responsive
element (HRE). Transcription of many cellular genes is thus in-
duced, which are beneﬁcial for cells to adapt to, or to cope with,
hypoxic environments. Some genes, especially those with multiple
HREs in their regulatory region, are readily induced by HIF alone,
while other genes require cooperation of transcription factors
other than HIF for maximal induction of transcription; thus, the
set of genes induced by hypoxia is not the same in every cell and
Fig. 3. Hypoxia-induced changes in ceramide moieties of sphingolipids in cultured human colon cancer cells. Caco-2M cells [8] were cultured under normoxic conditions
(normoxia), hypoxic conditions (1% O2) for 7 days (hypoxia), or hypoxic conditions for 7 days followed by normoxic conditions for 24 h (hypoxia + reoxygenation). Lipids were
extracted and analyzed by HPLC–ESI-MS/MS according to the protocol shown in [35]. (Panel A) Effects of hypoxia on sphingolipids having dihydrosphingosine LCB (d18:0,
sphinganine). (Panel B) Effects of hypoxia on sphingolipids having sphingosine LCB (d18:1) with ceramides. (Panel C) Effects of hypoxia on the ratio of monounsaturated/
saturated VLCFAs (sum of monounsaturated C20:1–C26:1/sum of saturated C20–26) in the ceramide moiety of sphingolipids. *P < 0.05; **P < 0.01; ***P < 0.001. Panel D
indicates the results of RT-PCR analyses of gene transcription involved in sphingolipid synthesis indicating signiﬁcant transcriptional induction of LASS1 (CerS1) and FA2H by
hypoxia. Transcription of LASS3 (CerS3) was markedly reduced. Only modest changes were observed in transcription of other genes.
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ids and gangliosides upon hypoxic culture depending on the cells
used in experiments.
6. Paradoxical effects of hypoxia-induced genes in cancers
Hypoxia-induced gene transcription is usually reversible in nor-
mal cells, since re-oxygenation rapidly restores ubiquitination of
the a-subunit of HIF in normal cells. On the other hand, cancer cells
acquire hypoxia resistance through sustained HIF expression, in
most cases by irreversibly interfering with HIF ubiquitination. For
instance, loss of anti-oncogenes such as p53 or VHL inhibits ubiqui-
tination of HIF and leads to its sustained nuclear translocation. Tu-
mor hypoxia promotes malignant progression by facilitating
selection and clonal expansion of the more aggressive cancer cells,
which can overcome oxygen deprivation or escape the hypoxic
environments. Such cancer cells have constitutively elevated tran-
scription of hypoxia-inducible genes even if under the normoxic
condition. Once HIF is irreversibly activated, cancer cells tend to
exhibit enhanced expression of sialyl Lewis A/X or Hanganatziu–
Deicher gangliosides, irrespective of oxygen tension in their
environments.
This sometimes leads to paradoxical consequences, especially
when the enzymes require oxygen for their catalytic activity. Someof the genes for enzymes requiring oxygen are induced under hyp-
oxic conditions in normal cells, but enzymatic products are not
effectively generated because of paucity of oxygen. On the other
hand, when genes for such enzymes are irreversibly induced in
cancer cells, this sometimes leads to an abnormal overproduction
of primary enzymatic metabolites, because of sustained gene tran-
scription even under normoxic conditions. There are not many en-
zymes requiring oxygen for glycan synthesis, while many such
enzymes are involved in lipid synthesis, such as in biosynthesis
of sphingolipids and plasmalogens, or in hydroxylation and unsat-
uration of fatty acids, where the paradoxical effects may be ob-
served in cancers.
7. Increase of cancer speciﬁcity by combination of multiple
tumor-associated changes
Malignant transformation affects cell-surface glycan expression
through various mechanisms [29]. One of the major mechanisms is
so-called incomplete synthesis of glycans. For instance, mature
nerve cells express higher gangliosides such as GD1a and GM1,
but malignant neuroblastoma cells frequently express shorter gan-
gliosides such as GM2 or GD3. Cancer cells tend to express shorter
chain glycolipids compared to the corresponding non-malignant
cells of the same tissue origin, and this is mainly due to epigenetic
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complex gangliosides (Fig. 4). Similarly, normal epithelial cells ex-
press sialyl 6-sulfo Lewis X and disialyl Lewis A, the glycans having
more complex structures than cancer-associated glycans, sialyl Le-
wis X and sialyl Lewis A. Epigenetic silencing of genes involved in
GlcNAc 6-sulfation or a2-6 sialylation upon carcinogenesis results
in the appearance of sialyl Lewis X and sialyl Lewis A in cancer cells
[30–32]. This mechanism affects cancer cell glycans at the rela-
tively early stages of carcinogenesis. This mechanism, however, is
not strictly cancer-speciﬁc, since a similar set of genes is some-
times silenced epigenetically also under non-malignant conditions
such as in inﬂammatory diseases.
Later in the locally advanced tumor stages, cancer cells cope and
overcome hypoxic environments by acquiring hypoxia-resistance.
This process further promotes changes in cell-surface glycans.
These hypoxia-induced changes are also not strictly cancer-spe-
ciﬁc, since a similar set of genes is also induced by hypoxia in
non-malignant diseases such as ischemic disorders. It means that
the Hanganatziu–Deicher gangliosides are not strictly speciﬁc to
cancers, but can appear in non-malignant cells under chronic hyp-
oxic conditions. Normal gangliosides would acquire N-glycolyl sia-
lic acid under hypoxic conditions, and such gangliosides may not
serve as speciﬁc markers for cancers.
When, however, well-known cancer-associated gangliosides,
such as GM2 or GD3, are modiﬁed by N-glycolyl sialic acid, such
gangliosides exhibit higher cancer speciﬁcity, and are competent
to serve as excellent markers of cancer cells. If normal neural tis-
sues were attacked by hypoxia, normal gangliosides such as GM1
and GD1a would be mainly modiﬁed by N-glycolyl sialic acid. It
is noteworthy that the glycan molecules reﬂecting the combined
effects of both epigenetic silencing and tumor hypoxia have rela-
tively higher cancer speciﬁcity. The GM2 ganglioside having N-gly-
colyl sialic acid could be one of such examples.
The same principle can be applied to other cancer-associated
glycans such as sialyl Lewis X and sialyl Lewis A carrying N-gly-Fig. 4. Schematic representation of cancer-associated changes of glycolipids,
exempliﬁed by GM2. Epigenetic silencing of a part of genes required for normal
complex glycolipids results in accumulation of shorter glycolipids such as GM2 at
the relatively early stages of carcinogenesis. Elevated transcription of the gene for
bGalNAc transferase is also noted in cancers [48], which occurs independent of
tumor hypoxia. Cancer cells acquire hypoxia tolerance in the locally advanced
stages, and this leads to alterations in both glycan moiety and ceramide moiety of
glycolipid. The molecular species of glycolipids exhibiting combination of multiple
tumor-associated changes are expected to have higher cancer speciﬁcity.colyl sialic acid. Modiﬁcation of cancer-associated glycans by N-
glycolyl sialic acid would further improve their cancer speciﬁcity.
In contrast, if normal epithelial cells were subjected to hypoxic
condition, normal glycans in epithelial cells such as sialyl 6-sulfo
Lewis X and disialyl Lewis A would be mainly modiﬁed by N-gly-
colyl sialic acid.8. Cancer-associated changes affect both glycan and ceramide
moieties of glycolipids
Our results as described here indicated that tumor hypoxia af-
fects not only glycan moiety, but also the ceramide moiety of tu-
mor-associated glycolipids. For instance, it could be suggested
that the tumor-associated glycolipids having DHCer moiety with
less unsaturated very long-chain fatty acids would have higher
cancer speciﬁcity.
To date detection of cancer-associated glycans largely relied on
the use of speciﬁc monoclonal antibodies. A good example is an
antibody speciﬁc to the GM2 ganglioside having N-glycolyl sialic
acid. Such a ganglioside having DHCer would be more speciﬁc to
hypoxia-resistant clones of cancer cells. Although the ceramide
moiety of glycolipid is known to signiﬁcantly affect its antigenicity
[33], it is difﬁcult to expect anti-glycolipid antibodies to speciﬁ-
cally detect glycolipids having deﬁnite molecular species of cera-
mide. In contrast, mass-spectrometry is theoretically best ﬁt for
this purpose, because it directly detects molecular species of cera-
mide moiety of given glycolipids [34,35].
9. Clinical application of glycolipids as future cancer markers
detected by mass spectrometry
An increasing number of papers has reported examples of suc-
cessful large-scale routine determination of glycolipids from small
amounts of clinical samples using mass-spectrometry. A signiﬁcant
increase in plasma ceramide levels was detected in type 2 diabetic
patients accompanied with C18:1 and C18:0 subspecies [36]. An
increased plasma level of ceramide was shown to be a risk factor
also for early atherosclerosis using LC–MS/MS [37]. Determination
of urinary globotriaosylceramide levels by LC–MS/MS is used for
screening of Fabry disease [38]. Matrix-assisted laser desorption
mass-spectrometry (MALDI-MS) is successfully applied for detec-
tion of ceramides or non-sialylated glycolipids such as monohexo-
syl ceramide and sulfatide [39–41]. Although these methods
utilizing mass spectrometry supply precious information on the
ceramide composition, the pathophysiological signiﬁcance and
clinical utility of such information do not seem to be widely appre-
ciated. Recent methods applying mass spectrometry for detection
of disease-marker glycolipids in patients sera or tissue samples
sometimes include procedures to isolate the glycan portion from
glycolipids through chemical or enzymatic cleavage [42–44]. Infor-
mation on ceramide moiety becomes unavailable by such
procedures.
Quality of tissue imaging by matrix-assisted laser desorption
mass-spectrometry (MALDI-MS) is signiﬁcantly improved recently
[45–47]. At present the sensitivity and resolution are not enough
for detection of minor molecular species, but ultimately, the imag-
ing MALDI-MS should be able to demonstrate hypoxic lesions in
tissue sections, which are occupied by cancer cells expressing the
cancer-associated glycolipids exhibiting a distinct long-chain base
and amide-linked fatty acid composition. Differential display of the
ratio of hypoxia-related molecular species of ceramide moiety of a
given cancer-associated glycolipid to those non-related normoxic
constituents using appropriate software will help to obtain more
clear imaging of tumor cell nests composed of hypoxia-resistant
cancer cells.
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